Kontsevoĭ V A, Medvedev A V, Andrusenko M P, Zvenigorodskaia Iu V, Sheshenin V S
Zh Nevrol Psikhiatr Im S S Korsakova. 1997;97(6):39-44.
Open study was performed concerning the efficiency of cerebrolysin in treatment of tardive dyskinesia and parkinsonism. 30 patients of middle (18-41 years) and old (60-82 years) age were examined by means of Extrapyramidal Symptom Rating Scale and Abnormal Involuntary Movement Scale. Cerebrolysin was administered intravenously by drops every other day in a dose of 5-10 ml during 28 days. Significant decrease of the severity of extrapyramidal symptoms (according to the Scales used) was observed by the end of the course of therapy. The number of the responders was 46.6%, of the partial responders--26.6%. Efficiency of cerebrolysin was the same both in the groups of patients with drug-induced parkinsonism (number of the responders--54.5%) and in patients with tardive dyskinesia (the responders' number--60%). The efficiency of cerebrolysin was lower in patients with combination of symptoms of parkinsonism and tardive dyskinesia as well as in ones with pronounced negative schizophrenic disorders in clinical picture. Efficacy of cerebrolysin was also the same in patients of both middle and old age. Its efficiency was equally high independently on the duration of extrapyramidal disorders' existence.
开展了一项关于脑蛋白水解物治疗迟发性运动障碍和帕金森症疗效的开放性研究。通过锥体外系症状评定量表和异常不自主运动量表对30名年龄在中年（18 - 41岁）和老年（60 - 82岁）的患者进行了检查。脑蛋白水解物每隔一天静脉滴注一次，剂量为5 - 10毫升，持续28天。在治疗疗程结束时，观察到锥体外系症状的严重程度（根据所使用的量表）显著降低。有反应者的比例为46.6%，部分有反应者的比例为26.6%。脑蛋白水解物在药物性帕金森症患者组（有反应者的比例为54.5%）和迟发性运动障碍患者组（有反应者的比例为60%）中的疗效相同。在帕金森症和迟发性运动障碍症状合并出现的患者以及临床表现有明显阴性精神分裂症障碍的患者中，脑蛋白水解物的疗效较低。脑蛋白水解物在中年和老年患者中的疗效也相同。无论锥体外系疾病存在的时长如何，其疗效同样很高。
